Humacyte, Inc.(HUMA)Stock Analysis

HUMA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Humacyte, Inc. (HUMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HUMA at 5.0/100 on a 32-signal composite quality model, placing it at rank #2,850 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.7) and revenue scale (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Humacyte, Inc. reports quarterly revenue of $495.0K, net income of $-17.6M, free cash flow of $-25.3M. Top institutional holders of HUMA by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, ANTIPODES PARTNERS Ltd, based on the most recent SEC filings. HUMA trades on the Nasdaq exchange and files with the SEC under CIK 1818382. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HUMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Humacyte, Inc. directly from SEC EDGAR. Humacyte, Inc.'s 13F Pro composite quality score has ranged between 5 and 27 since 2026, currently 5.0 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.